https://slenterprise.com/index.php/news/7714-industry-briefs-10-21-24 RECOGNITIONS This year’s PharmaVoice 100 honorees list includes David Bearss, CEO, president and co-founder of Halia Therapeutics, a Lehi-based company developing therapies addressing chronic...

Combination with NLRP3 inhibitor achieves 50% greater weight loss and lean muscle preservation in mice than with semaglutide alone. As featured in Longevity.Technology "Inflammation-targeting biotech Halia Therapeutics has reported promising preclinical results from a...

https://podcast.labiotech.eu/1995493/episodes/15734215-targeting-inflammation-a-revolution-in-disease-treatment Inflammation appears to affect almost every part of the human body as we age, including cancer, type-2 diabetes, obesity, and neurodegenerative disorders....

The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2024 Prix Galien USA Award nominees for "Best Digital Health Solution," "Best Medical Technology," and "Incubators, Accelerators and Equity."...

By Jill Drachenberg -- BioSpace July 15, 2024 Halia Therapeutics, NodThera and Gain Therapeutics target neuroinflammatory processes in hopes of modifying the course of Parkinson’s progression. Preventing or reversing neuroinflammation could be the next clinical...

Charleston, South Carolina, June 5, 2024 – John Kauwe Ph.D., a 2013 CCAD awardee shares how CCAD made a difference in his research career. Kauwe is the president of BYU-Hawaii and owner of Halia Therapeutics, a company that discovers and develops novel...

By Joe Petroziello -- Pharmaceutical Executive June 13, 2024 Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions. During BIO International Convention 2024, CEO Dave Bearss, PhD, of Halia...

Chronic inflammation goes hand-in-hand with many diseases, complicating symptoms and affecting routes of treatment. What is the molecular basis of inflammation, and can it be targeted by new drugs? Scientists have studied the molecular basis of the inflammatory...

Venture Capital Podcast has released their Founder 100 honoree list for Utah. It is a crowd-nominated, peer-voted list of the state's top founders in terms of their attractiveness to investors. The honorees and a large group of investors will meet this evening in a...

By Brittny Goodsell -- Utah Business Magazine David Bearss, CEO of Halia Therapeutics, says his company uses Carta to manage multiple things. “Biotech companies are always in need of large capital raises to support the expenses from clinical development of new...

By Heather Bergerson -- Utah Business Magazine Utah-based companies Halia Therapeutics and Canary Speech are collaborating to revolutionize how Alzheimer's disease can be monitored and treated. https://bit.ly/3z2AhkH

Beyond Employee Engagement: Unpacking Performance in Life Sciences Leadership - Executive Roundtable April 1, 2024 In this insightful episode of Conversations Life Science Leaders Aren't Having, Jeff Harmon hosts an invaluable Life Science Executive Roundtable. The...

March 20, 2024/28:57/E24012 In this episode of BioTech Nation, Dr. David Bearss, President, and CEO of Halia Therapeutics, discusses inflammation and its reduction over a lifetime and in response to various incidents. He unveils the inflammasome, a recently discovered...

The study will enroll up to 80 adults who are undergoing the surgical removal of two or more molar teeth for inflammatory and pain management. February 16, 2024 US-based biopharmaceutical company Halia Therapeutics has begun a Phase II clinical trial to...